Refractory sarcoidosis responding to infliximab

Chest. 2003 Nov;124(5):2028-31. doi: 10.1378/chest.124.5.2028.


Despite aggressive treatment with conventional therapy, sarcoidosis may be progressive and debilitating. Tumor necrosis factor (TNF)-alpha is critical in the genesis and maintenance of granulomatous inflammation. Agents developed to inhibit TNF-alpha have been approved to treat rheumatoid arthritis and inflammatory bowel disease with unprecedented success. As such, physicians are increasingly using these agents to treat patients with other inflammatory diseases, including sarcoidosis. We report a case of refractory sarcoidosis, involving the lung, eyes, skin, and heart, which flared despite aggressive therapy. Oculocutaneous sarcoid dramatically improved after treatment with the anti-TNF antibody infliximab.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Drug Resistance
  • Drug Therapy, Combination
  • Female
  • Glucocorticoids / therapeutic use
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Infliximab
  • Middle Aged
  • Prednisone / therapeutic use
  • Sarcoidosis / drug therapy*
  • Sarcoidosis / pathology
  • Skin Diseases / drug therapy
  • Tumor Necrosis Factor-alpha / immunology


  • Antibodies, Monoclonal
  • Glucocorticoids
  • Immunosuppressive Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab
  • Prednisone